Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis
To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive mutation. Following a systematic literature review until December 2019, we conducted a random-effects pairw...
Gespeichert in:
| Veröffentlicht in: | Lung cancer management 2020-11, Vol.10 (1), p.LMT43 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 1 |
| container_start_page | LMT43 |
| container_title | Lung cancer management |
| container_volume | 10 |
| creator | Alanazi, Abdullah Yunusa, Ismaeel Elenizi, Khaled Alzarea, Abdulaziz I |
| description | To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive
mutation.
Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.
In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient’s individual clinical characteristics. |
| doi_str_mv | 10.2217/lmt-2020-0011 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7724735</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2478333783</sourcerecordid><originalsourceid>FETCH-LOGICAL-c531t-5ccb497e32a1308bb87014accf9b2dd3ee11ba3922409f092dd06cf81d26646c3</originalsourceid><addsrcrecordid>eNp1kcuOFCEUhonROJN2lm4NiWuUS11dmJjJeEkmcaNrcoo6dDNTBS1QM-m3mZUP4pNJpceOLmQBh3M-fuD8hLwU_I2Uon07zZlJLjnjXIgn5Fy0dcdE31ZPT3HTnJGLlG54GS2XTaWekzOllOjauj4nP6-sdQbMgYIfaQKL-UCDpfkQQ3Ie6a3zkJA6v3ODyyGmElIY78AbHKkPnqUZpokZnCY6LX5LzVqKvx52EIcQXcng3o0YC0a3MdznHbVgihSNaHC_BvOSIbvg31GgHvN9iLd0xgwMPEyH5NIL8szClPDicd2Q7x-vvl1-ZtdfP325_HDNTK1EZrUxQ9W3qCQIxbth6FouKjDG9oMcR4UoxACql7LiveV9yfHG2E6MsmmqxqgNeX_U3S_DjKNBnyNMeh_dDPGgAzj9b8W7nd6GO922smpVXQRePwrE8GPBlPVNWGL5RdIF6Erj12lD2JEypcspoj3dILhendXFWb06q1dnC__q72ed6D8-FqA_AnbJS8RkHBYT9HFXTjhTvPyP-G-QJrih</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2478333783</pqid></control><display><type>article</type><title>Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis</title><source>Taylor & Francis Open Access</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Alanazi, Abdullah ; Yunusa, Ismaeel ; Elenizi, Khaled ; Alzarea, Abdulaziz I</creator><creatorcontrib>Alanazi, Abdullah ; Yunusa, Ismaeel ; Elenizi, Khaled ; Alzarea, Abdulaziz I</creatorcontrib><description>To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive
mutation.
Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.
In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient’s individual clinical characteristics.</description><identifier>ISSN: 1758-1966</identifier><identifier>EISSN: 1758-1974</identifier><identifier>DOI: 10.2217/lmt-2020-0011</identifier><identifier>PMID: 33318755</identifier><language>eng</language><publisher>England: Future Medicine Ltd</publisher><subject>Bias ; Cancer therapies ; Chemotherapy ; Clinical trials ; Cytotoxicity ; Drugs ; Epidermal growth factor ; epidermal growth factor receptor ; Kinases ; Lung cancer ; Meta-Analysis ; Mutation ; network meta-analysis ; Patients ; Population ; Software ; Targeted cancer therapy ; tyrosine kinase inhibitors</subject><ispartof>Lung cancer management, 2020-11, Vol.10 (1), p.LMT43</ispartof><rights>2020 Abdullah Alanazi, Ismaeel Yunusa and Khaled Elenizi</rights><rights>2020 Abdullah Alanazi, Ismaeel Yunusa and Khaled Elenizi.</rights><rights>2021. This work is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2020 Abdullah Alanazi, Ismaeel Yunusa and Khaled Elenizi 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c531t-5ccb497e32a1308bb87014accf9b2dd3ee11ba3922409f092dd06cf81d26646c3</citedby><cites>FETCH-LOGICAL-c531t-5ccb497e32a1308bb87014accf9b2dd3ee11ba3922409f092dd06cf81d26646c3</cites><orcidid>0000-0002-9107-8561 ; 0000-0003-0604-6299 ; 0000-0003-0316-1523 ; 0000-0002-8120-4018</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724735/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724735/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27915,27916,53782,53784</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33318755$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Alanazi, Abdullah</creatorcontrib><creatorcontrib>Yunusa, Ismaeel</creatorcontrib><creatorcontrib>Elenizi, Khaled</creatorcontrib><creatorcontrib>Alzarea, Abdulaziz I</creatorcontrib><title>Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis</title><title>Lung cancer management</title><addtitle>Lung Cancer Manag</addtitle><description>To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive
mutation.
Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.
In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient’s individual clinical characteristics.</description><subject>Bias</subject><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Clinical trials</subject><subject>Cytotoxicity</subject><subject>Drugs</subject><subject>Epidermal growth factor</subject><subject>epidermal growth factor receptor</subject><subject>Kinases</subject><subject>Lung cancer</subject><subject>Meta-Analysis</subject><subject>Mutation</subject><subject>network meta-analysis</subject><subject>Patients</subject><subject>Population</subject><subject>Software</subject><subject>Targeted cancer therapy</subject><subject>tyrosine kinase inhibitors</subject><issn>1758-1966</issn><issn>1758-1974</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp1kcuOFCEUhonROJN2lm4NiWuUS11dmJjJeEkmcaNrcoo6dDNTBS1QM-m3mZUP4pNJpceOLmQBh3M-fuD8hLwU_I2Uon07zZlJLjnjXIgn5Fy0dcdE31ZPT3HTnJGLlG54GS2XTaWekzOllOjauj4nP6-sdQbMgYIfaQKL-UCDpfkQQ3Ie6a3zkJA6v3ODyyGmElIY78AbHKkPnqUZpokZnCY6LX5LzVqKvx52EIcQXcng3o0YC0a3MdznHbVgihSNaHC_BvOSIbvg31GgHvN9iLd0xgwMPEyH5NIL8szClPDicd2Q7x-vvl1-ZtdfP325_HDNTK1EZrUxQ9W3qCQIxbth6FouKjDG9oMcR4UoxACql7LiveV9yfHG2E6MsmmqxqgNeX_U3S_DjKNBnyNMeh_dDPGgAzj9b8W7nd6GO922smpVXQRePwrE8GPBlPVNWGL5RdIF6Erj12lD2JEypcspoj3dILhendXFWb06q1dnC__q72ed6D8-FqA_AnbJS8RkHBYT9HFXTjhTvPyP-G-QJrih</recordid><startdate>20201123</startdate><enddate>20201123</enddate><creator>Alanazi, Abdullah</creator><creator>Yunusa, Ismaeel</creator><creator>Elenizi, Khaled</creator><creator>Alzarea, Abdulaziz I</creator><general>Future Medicine Ltd</general><scope>FUMOA</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-9107-8561</orcidid><orcidid>https://orcid.org/0000-0003-0604-6299</orcidid><orcidid>https://orcid.org/0000-0003-0316-1523</orcidid><orcidid>https://orcid.org/0000-0002-8120-4018</orcidid></search><sort><creationdate>20201123</creationdate><title>Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis</title><author>Alanazi, Abdullah ; Yunusa, Ismaeel ; Elenizi, Khaled ; Alzarea, Abdulaziz I</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c531t-5ccb497e32a1308bb87014accf9b2dd3ee11ba3922409f092dd06cf81d26646c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Bias</topic><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Clinical trials</topic><topic>Cytotoxicity</topic><topic>Drugs</topic><topic>Epidermal growth factor</topic><topic>epidermal growth factor receptor</topic><topic>Kinases</topic><topic>Lung cancer</topic><topic>Meta-Analysis</topic><topic>Mutation</topic><topic>network meta-analysis</topic><topic>Patients</topic><topic>Population</topic><topic>Software</topic><topic>Targeted cancer therapy</topic><topic>tyrosine kinase inhibitors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Alanazi, Abdullah</creatorcontrib><creatorcontrib>Yunusa, Ismaeel</creatorcontrib><creatorcontrib>Elenizi, Khaled</creatorcontrib><creatorcontrib>Alzarea, Abdulaziz I</creatorcontrib><collection>Future Medicine (Open Access)</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Lung cancer management</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Alanazi, Abdullah</au><au>Yunusa, Ismaeel</au><au>Elenizi, Khaled</au><au>Alzarea, Abdulaziz I</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis</atitle><jtitle>Lung cancer management</jtitle><addtitle>Lung Cancer Manag</addtitle><date>2020-11-23</date><risdate>2020</risdate><volume>10</volume><issue>1</issue><spage>LMT43</spage><pages>LMT43-</pages><issn>1758-1966</issn><eissn>1758-1974</eissn><abstract>To compare the efficacy and safety of tyrosine kinase inhibitors (TKIs) as first-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) with positive
mutation.
Following a systematic literature review until December 2019, we conducted a random-effects pairwise and network meta-analyses (NMA). We ranked treatments for efficacy and safety based on the surface under the cumulative ranking curve (SUCRA).
Tyrosine kinase inhibitors of the epidermal growth factor receptor (EGFR-TKI) improved survival outcomes with fewer grade 3 or higher adverse events compared to chemotherapy. Overall survival results suggest that osimertinib has the highest probability of being the most efficacious (SUCRA, 79.9%), followed by dacomitinib (SUCRA, 75.8%). Adverse events results suggest that osimertinib (SUCRA, 84.3%) and gefitinib (SUCRA, 78.9%) has the highest probability of being the safest.
In this NMA, we found that osimertinib is the most efficacious and safest EGFR-TKI. These results may guide clinicians in choosing the most appropriate treatment option among EGFR-TKIs for their patient’s individual clinical characteristics.</abstract><cop>England</cop><pub>Future Medicine Ltd</pub><pmid>33318755</pmid><doi>10.2217/lmt-2020-0011</doi><orcidid>https://orcid.org/0000-0002-9107-8561</orcidid><orcidid>https://orcid.org/0000-0003-0604-6299</orcidid><orcidid>https://orcid.org/0000-0003-0316-1523</orcidid><orcidid>https://orcid.org/0000-0002-8120-4018</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1758-1966 |
| ispartof | Lung cancer management, 2020-11, Vol.10 (1), p.LMT43 |
| issn | 1758-1966 1758-1974 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7724735 |
| source | Taylor & Francis Open Access; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Bias Cancer therapies Chemotherapy Clinical trials Cytotoxicity Drugs Epidermal growth factor epidermal growth factor receptor Kinases Lung cancer Meta-Analysis Mutation network meta-analysis Patients Population Software Targeted cancer therapy tyrosine kinase inhibitors |
| title | Efficacy and safety of tyrosine kinase inhibitors in advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutation: a network meta-analysis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T07%3A03%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Efficacy%20and%20safety%20of%20tyrosine%20kinase%20inhibitors%20in%20advanced%20non-small-cell%20lung%20cancer%C2%A0harboring%20epidermal%20growth%20factor%20receptor%20mutation:%20a%20network%20meta-analysis&rft.jtitle=Lung%20cancer%20management&rft.au=Alanazi,%20Abdullah&rft.date=2020-11-23&rft.volume=10&rft.issue=1&rft.spage=LMT43&rft.pages=LMT43-&rft.issn=1758-1966&rft.eissn=1758-1974&rft_id=info:doi/10.2217/lmt-2020-0011&rft_dat=%3Cproquest_pubme%3E2478333783%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2478333783&rft_id=info:pmid/33318755&rfr_iscdi=true |